3.94
0.00%
+0.00
After Hours:
4.00
0.06
+1.52%
Aldeyra Therapeutics Inc stock is currently priced at $3.94, with a 24-hour trading volume of 455.59K.
It has seen a +0.00% increased in the last 24 hours and a +36.81% rose in the past month.
The chart indicates a potential bullish trend, as the stock is above the $3.94 pivot point. If it approaches the $4.00 resistance level, significant changes may occur.
Previous Close:
$3.94
Open:
$3.9
24h Volume:
455.59K
Market Cap:
$234.09M
Revenue:
-
Net Income/Loss:
$-37.54M
P/E Ratio:
-4.427
EPS:
-0.89
Net Cash Flow:
$-30.33M
1W Performance:
-1.01%
1M Performance:
+36.81%
6M Performance:
+154.19%
1Y Performance:
-56.61%
Aldeyra Therapeutics Inc Stock (ALDX) Company Profile
Name
Aldeyra Therapeutics Inc
Sector
Industry
Phone
781-761-4904
Address
131 Hartwell Avenue, Suite 320, Lexington, MA
Aldeyra Therapeutics Inc Stock (ALDX) Upgrades & Downgrades
Date | Action | Analyst | Rating Change |
---|---|---|---|
Apr-27-22 | Resumed | H.C. Wainwright | Buy |
Feb-08-21 | Initiated | H.C. Wainwright | Buy |
Dec-16-20 | Initiated | Berenberg | Buy |
Oct-30-20 | Initiated | Jefferies | Buy |
Oct-16-20 | Initiated | BTIG Research | Buy |
Sep-22-20 | Initiated | Alliance Global Partners | Buy |
May-12-20 | Initiated | Oppenheimer | Outperform |
Dec-04-18 | Initiated | Citigroup | Buy |
Sep-26-18 | Reiterated | Cantor Fitzgerald | Overweight |
Sep-13-18 | Initiated | Janney | Buy |
Jan-26-18 | Initiated | Seaport Global Securities | Buy |
Sep-26-16 | Initiated | H.C. Wainwright | Buy |
Jul-01-16 | Initiated | Stifel | Buy |
Jul-01-15 | Initiated | Canaccord Genuity | Buy |
Mar-25-15 | Initiated | Chardan Capital Markets | Buy |
Mar-20-15 | Reiterated | H.C. Wainwright | Buy |
Nov-18-14 | Initiated | H.C. Wainwright | Buy |
Jun-19-14 | Initiated | Aegis Capital | Buy |
View All
Aldeyra Therapeutics Inc Stock (ALDX) Latest News
Is Aldeyra Therapeutics (ALDX) Outperforming Other Medical Stocks This Year?
Zacks Investment Research
Aldeyra (ALDX) Stock Rallies 43% in One Week: Here's Why
Zacks Investment Research
Are Medical Stocks Lagging Aclaris Therapeutics (ACRS) This Year?
Zacks Investment Research
Aldeyra Therapeutics And 2 Other Stocks Under $5 Insiders Are Buying
Benzinga
Here's Why You Should Invest in Aldeyra (ALDX) Stock Now
Zacks Investment Research
Is Aclaris Therapeutics (ACRS) Outperforming Other Medical Stocks This Year?
Zacks Investment Research
Aldeyra Therapeutics Inc Stock (ALDX) Financials Data
Aldeyra Therapeutics Inc (ALDX) Net Income 2024
ALDX net income (TTM) was -$37.54 million for the quarter ending December 31, 2023, a +39.47% increase year-over-year.
Aldeyra Therapeutics Inc (ALDX) Cash Flow 2024
ALDX recorded a free cash flow (TTM) of -$30.33 million for the quarter ending December 31, 2023, a +46.47% increase year-over-year.
Aldeyra Therapeutics Inc (ALDX) Earnings per Share 2024
ALDX earnings per share (TTM) was -$0.64 for the quarter ending December 31, 2023, a +39.62% growth year-over-year.
About Aldeyra Therapeutics Inc
Aldeyra Therapeutics, Inc. engages in developing medicines for inflammatory diseases. The company's lead product candidate is reproxalap, an ophthalmic solution, which is in Phase 2b clinical trial for the treatment of dry eye disease, as well as Phase 3 clinical trial for the treatment of noninfectious anterior uveitis. Its reproxalap is also in Phase 2b clinical trial for the treatment of allergic conjunctivitis, as well as Phase 2 clinical trial for the treatment of Sjögren-Larsson Syndrome. Its portfolio consists of ADX-1612, which inhibits heat shock protein 90 for the treatment of lymphoproliferative diseases; and reactive aldehyde species that are pro-inflammatory (RASP) scavengers, such as ADX-629 and ADX-103. Aldeyra Therapeutics, Inc. has a partnership agreement with Janssen to develop other RASP scavengers for immune-mediated diseases. The company was formerly known as Aldexa Therapeutics, Inc. and changed its name to Aldeyra Therapeutics, Inc. in March 2014. Aldeyra Therapeutics, Inc. was founded in 2004 and is headquartered in Lexington, Massachusetts.
Cap:
|
Volume (24h):